Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Tsigos, Constantine ^a   Bitzur, Rafael ^b   Kleinman, Yosef ^c   Cohen, Hofit ^b   Cahn, Avivit ^d   Brambilla, Gianmaria ^e   Mancia, Giuseppe ^e   Grassi, Guido ^e,f  

^a HYGEIA HOSPITAL   (Greece)

^b SHEBA MEDICAL CENTER   (Israel)

^c BIKUR CHOLIM HOSPITAL   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADL DISABILITY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CORRELATIONAL STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL DISEASE; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; MORTALITY; MYALGIA; NURSING HOME PATIENT; OBESITY; POLYPHARMACY; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK FACTOR; UNDERWEIGHT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADIPOSE TISSUE; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; BODY MASS INDEX; HEALTH; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIPIDS; OBESITY;

EID: 84891782088     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2021     Document Type: Article

References (69)

1. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187
2. Tsigos C, Hainer V, Basdevant A, et al.; Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008;1:106-116
3. Reiner Z, Catapano AL, De Backer G, et al.; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818
4. Centers for Disease Control and Prevention. National diabetes fact sheet 2011 [article online]. Available from http://www.cdc.gov/diabetes/pubs/pdf/ndfs- 2011.pdf. Accessed 31 January 2013
5. Villareal DT, Apovian CM, Kushner RF, Klein S; American Society for Nutrition; NAASO, The Obesity Society. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005;82:923-934
6. Aronow WS, Fleg JL, Pepine CJ, et al.; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123:2434-2506
7. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008;263:336-352
8. Arterburn DE, Crane PK, Sullivan SD. The coming epidemic of obesity in elderly Americans. J Am Geriatr Soc 2004;52: 1907-1912
9. Kyrou I, Tsigos C. Obesity in the elderly diabetic patient: is weight loss beneficial? No. Diabetes Care 2009;32(Suppl. 2): S403-S409
10. Mathus-Vliegen EM; Obesity Management Task Force of the European Association for the Study of Obesity. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: a guideline. Obes Facts 2012;5:460-483
11. Gallagher D, Visser M, Sepúlveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996; 143:228-239
12. Visscher TL, Seidell JC, Molarius A, van der Kuip D, Hofman A, Witteman JC. A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study. Int J Obes Relat Metab Disord 2001;25:1730-1735
13. Shimokata H, Andres R, Coon PJ, Elahi D, Muller DC, Tobin JD. Studies in the distribution of body fat. II. Longitudinal effects of change in weight. Int J Obes 1989; 13:455-464
14. Seidell JC, Visscher TL. Body weight and weight change and their health implications for the elderly. Eur J Clin Nutr 2000;54(Suppl. 3):S33-S39
15. Janssen I, Mark AE. Elevated body mass index and mortality risk in the elderly. Obes Rev 2007;8:41-59
16. Lang IA, Llewellyn DJ, Alexander K, Melzer D. Obesity, physical function, and mortality in older adults. J Am Geriatr Soc 2008;56:1474-1478
17. Kuk JL, Ardern CI. Influence of age on the association between various measures of obesity and all-cause mortality. J Am Geriatr Soc 2009;57:2077-2084
18. Stessman J, Jacobs JM, Ein-Mor E, Bursztyn M. Normal body mass index rather than obesity predicts greater mortality in elderly people: the Jerusalem longitudinal study. J Am Geriatr Soc 2009;57:2232-2238
19. Han TS, Tajar A, Lean ME. Obesity and weight managementinthe elderly. Br Med Bull 2011;97:169-196
20. Caterson ID, Finer N, Coutinho W, et al.; SCOUT Investigators. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012;14:523-530
21. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367: 1577-1579
22. Ensrud KE, Cauley J, Lipschutz R, Cummings SR; Study of Osteoporotic Fractures ResearchGroup. Weight change and fractures in older women. Arch Intern Med 1997;157:857-863
23. Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S. Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin En-docrinol Metab 2008;93:2181-2187
24. Bales CW, Ritchie CS. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr 2002;22:309-323
25. Li Z, Heber D. Sarcopenic obesity in the elderly and strategies for weight management. Nutr Rev 2012;70:57-64
26. Wagner DR, Heyward VH. Techniques of body composition assessment: a review of laboratory and field methods. Res Q Exerc Sport 1999;70:135-149
27. Miller SL, Wolfe RR. The danger of weight loss in the elderly. J Nutr Health Aging 2008;12:487-491
28. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of he-mo dynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-659
29. Lutsey PL, Michos ED. Vitamin D, calcium, and atherosclerotic risk: evidence from serum levels and supplementation studies. Curr Atheroscler Rep 2013;15: 293
30. Li Z, Maglione M, Tu W, et al. Metaanalysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-546
31. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated metaanalysis. BMJ 2007;335:1194-1199
32. Fried M, Hainer V, Basdevant A, et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes (Lond) 2007;31:569-577
33. Turnbull F, Neal B, Ninomiya T, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-1123
34. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens 2010;28:1366-1372
35. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898
36. Beckett N, Peters R, Tuomilehto J, et al.; HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2012;344:d7541
37. Mancia G, Laurent S, Agabiti-Rosei E, et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
38. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008; 31:2115-2127
39. Grassi G, Quarti-Trevano F, Dell'Oro R, Mancia G. The "J curve" problem revisited: old and new findings. Curr Hypertens Rep 2010;12:290-295
40. D'Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-187
41. Conroy RM, Pyörälä K, Fitzgerald AP, et al.; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
42. Lewington S, Whitlock G, Clarke R, et al.; Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths. Lancet 2007;370:1829-1839
43. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993;153:1065-1073
44. Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997;126:753-760
45. Gränsbo K, Melander O, Wallentin L, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 2010;55:1362-1369
46. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
47. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R; Heart Protection Study Collaborative. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20, 536 people. BMJ 2006;333:1145-1149
48. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152: 488-496, W174
49. Shepherd J, Blauw GJ, Murphy MB, et al.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360: 1623-1630
50. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008;51:37-45
51. Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681
52. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-1802
53. Williams MA, Fleg JL, Ades PA, et al.; American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients. or =75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735-1743
54. Bethel MA, Sloan FA, Belsky D, Feinglos MN. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med 2007;167:921-927
55. Sinclair A, Morley JE, Rodriguez-Mañas L, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497-502
56. Diabetes Control and Complications Trial Research Group. Progression of retinop-athy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995;102:647-661
57. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853
58. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-upof intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
59. Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes melli-tus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012;172:761-769
60. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyper-glycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379
61. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35:2650-2664
62. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;1:CD002967
63. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-1437
64. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes [article online] 2009. Available from http://www.nice.org. uk/nicemedia/live/12165/44320/44320. pdf. Accessed 31 January 2013
65. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012;104:1411-1421
66. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; PROactive investigators. Impact of peripheral arterial disease in patients with diabetesdresults from PROactive (PROactive 11). Atherosclerosis 2009;202: 272-281
67. Nicholson G, Hall GM. Diabetes mellitus: new drugs for a new epidemic. Br J An-aesth 2011;107:65-73
68. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypo-glycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009;58:360-366
69. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglyce-mic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-1572